Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 21:13:45-56.
doi: 10.2147/COPD.S145573. eCollection 2018.

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Affiliations
Review

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Amnon Ariel et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups.

Keywords: LABA; LAMA; anticholinergic; dual bronchodilation; inhaled corticosteroid; tiotropium.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Estimated changes in FEV1 by GOLD group and severe-exacerbation status. Notes: The plot demonstrates that for each GOLD classification, those individuals with at least one severe exacerbation (dotted lines) had faster declines in FEV1 on average compared with those who did not (solid lines). GOLD 0, no airway obstruction; GOLD 1, mild; GOLD 2, moderate; GOLD 3, severe; GOLD 4, very severe. Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Dransfield MT, Kunisaki KM, Strand MJ, et al. 2017 Acute exacerbations and lung function loss in smokers with and without COPD. Am J Respir Crit Care Med. 2017;195:324–330. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society. Abbreviation: PRISm, preserved ratio-impaired spirometry.

Similar articles

Cited by

References

    1. Cohen JS, Miles MC, Donohue JF, Ohar JA. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis. 2016;11:785–797. - PMC - PubMed
    1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412. - PubMed
    1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276. - PubMed
    1. European Respiratory Society . European Lung White Book. Huddersfield, UK: ERS; 2003.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. - PMC - PubMed

MeSH terms

Substances